Skip to main content

About
News & Events
Careers
Contact
Subscribe

Find Reports
- Programs & Initiatives
- Methods
- Tools & Publications
- Provide Input
- Engage
- Community Involvement

Search

Find Reports
Our Work
- Programs & Initiatives
- Methods
- Tools & Publications
Get Involved
- Provide Input
- Engage
- Community Involvement

About
News & Events
Careers
Contact
Subscribe

Cladribine and Natalizumab for Relapsing-Remitting Multiple Sclerosis - Feedback Submission - Draft Recommendation - TS0004-000

Status message

Sorry… This form is closed to new submissions.

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact.

Reports
Contact
Careers
Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Email Address

Already subscribed? Update your preferences.

visit us on facebook
visit us on linkedin
visit us on youtube
visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

Privacy Policy
Terms of Use
Accessibility
Request for Archived Report